Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University.  The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Genmab

Vivo Capital

Rock Springs Capital

Samsara BioCapital

Sofinnova Investments

Surveyor Capital

Novo Holdings

Pfizer Venture Investments

Pivotal bioVenture Partners

RA Capital Management

Bolt Biotherapeutics, Inc. 

#BoltBio management will be in New York for the Guggenheim Partners Healthcare Talks Biotech Conference. We look forward to connecting in person!

Today is #WorldCancerDay, and members of #TeamBolt are running in support of The DONNA Foundation and its Fight to FINISH #BreastCancer. Learn more about the DONNA Foundation here: https://bit.ly/4b5oMaJ

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about The DONNA Foundation and their work to FINISH #breastcancer: https://bit.ly/48PVsUk 

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-11.59M -	-30.49M 163.07%	-60.73M 99.19%	-98.59M 62.35%	-88.10M 10.64%	-69.20M 21.45%
depreciation and amortization	302K -	335K 10.93%	611K 82.39%	1.19M 95.25%	1.67M 39.65%	1.85M 11.28%
deferred income tax			34K -	2.76M 8,023.53%
stock based compensation	123K -	508K 313.01%	1.42M 179.53%	8.50M 498.59%	9.58M 12.66%	9.22M 3.69%
change in working capital	1.14M -	2.27M 98.86%	-2.28M 200.79%	20.51M 998.25%	-3.06M 114.91%	-3.41M 11.65%
accounts receivables
inventory
accounts payables			2.88M -	6.68M 131.64%	2.77M 58.54%	-3.41M 223.30%
other working capital	1.14M -	2.27M 98.86%	-5.17M 328.04%	13.83M 367.78%	-5.83M 142.12%	3.41M 158.59%
other non cash items	153K -	1.04M 577.12%	13.64M 1,216.41%	8.56M 37.21%	3.41M 60.19%	-11.40M 434.56%
net cash provided by operating activities	-9.87M -	-26.34M 166.85%	-47.31M 79.58%	-57.07M 20.63%	-76.50M 34.06%	-69.53M 9.12%
investments in property plant and equipment	-290K -	-508K 75.17%	-3.26M 542.13%	-2.34M 28.33%	-1.95M 16.47%	-206K 89.45%
acquisitions net			17.33M -	229.86M 1,226.39%	-59.81M 126.02%
purchases of investments			-33.23M -	-313.38M 843.08%	-180.70M 42.34%	-164.99M 8.70%
sales maturities of investments			15.90M -	83.51M 425.27%	240.52M 188.01%	236.23M 1.78%
other investing activites			-17.33M -	-229.86M 1,226.39%	59.81M 126.02%
net cash used for investing activites	-290K -	-508K 75.17%	-20.59M 3,953.54%	-232.20M 1,027.63%	57.86M 124.92%	71.04M 22.77%
debt repayment	-39K -	-40K 2.56%
common stock issued	20K -	72K 260%	294K 308.33%	259.21M 88,065.31%	503K 99.81%	253K 49.70%
common stock repurchased				13.64M -
dividends paid
other financing activites	19.11M -	48.59M 154.25%	39.30M 19.12%	38.26M 2.64%
net cash used provided by financing activities	19.09M -	48.63M 154.67%	39.60M 18.57%	311.11M 685.69%	503K 99.84%	253K 49.70%
effect of forex changes on cash
net change in cash	8.93M -	21.78M 143.80%	-28.30M 229.97%	21.84M 177.17%	-18.14M 183.05%	1.77M 109.74%
cash at beginning of period	4.70M -	13.63M 189.96%	35.41M 159.72%	7.11M 79.93%	28.95M 307.32%	10.81M 62.66%
cash at end of period	13.63M -	35.41M 159.72%	7.11M 79.93%	28.95M 307.32%	10.81M 62.66%	12.57M 16.34%
operating cash flow	-9.87M -	-26.34M 166.85%	-47.31M 79.58%	-57.07M 20.63%	-76.50M 34.06%	-69.53M 9.12%
capital expenditure	-290K -	-508K 75.17%	-3.26M 542.13%	-2.34M 28.33%	-1.95M 16.47%	-206K 89.45%
free cash flow	-10.16M -	-26.85M 164.23%	-50.57M 88.34%	-59.40M 17.47%	-78.46M 32.07%	-69.73M 11.12%

NASDAQ:BOLT

Bolt Biotherapeutics

Last Close

0.74

26/07 20:00

Market Cap

27.47M

Beta: 0.99

Volume Today

138.00K

Avg: 250.78K

PE Ratio

−0.60

PFCF: −0.56

Preview